Magic Mushrooms Are Shaping the Future of Psychiatric Treatment
by Peter Hess
You may know the chemical 4-phosphoryloxy-N,N-dimethyltryptamine by its more common name, psilocybin. Long used as a sacrament among indigenous peoples in the Americas — and more recently branded as an illicit party drug — in recent years, the active ingredient in psychedelic mushrooms has received a lot of attention from scientists for potential to treat substance use disorder, anxiety, and depression. Adding to the growing body of scientific literature supporting psilocybin-based therapy, on May 8 a team of researchers reported in the Journal of Psychoactive Drugs that it’s even more effective than traditional psychiatric therapies.
In their review of seven published psilocybin clinical trials, the team led by Kelan
Thomas, assistant professor of clinical sciences at Touro University California, concluded
that psilocybin-assisted psychotherapy shows strong potential for improving outcomes in patients living with depression,
anxiety, and substance use disorder. The advantage of psilocybin-assisted therapy,
they write, is that it provides significant benefits for patients who haven’t responded
to therapy or medication. Patients can also show improvement after just a few six-hour
“medicated” therapy sessions and a few weeks of follow-up therapy.
Copyright 2005 - 2019, Touro University, All Rights Reserved.